title: [Halofantrine in the treatment of imported malaria in nonimmune travelers].
abstract: The efficacy (criteria: cure rate, time to resolution of fever or absence of parasites) and safety (criteria: clinical side effects, altered laboratory parameters) of halofantrin were investigated in a multi-centre study of 96 non-immune patients (71 men, 25 women, mean age 34.3 [21-62] years) with malaria imported from regions of high resistance into Germany or Switzerland. The initial 63 patients received one-day treatment (three doses of 500 mg halofantrin), while the last 33 patients received an additional course of treatment one week later. Treatment was curative in all patients in the second group, but relapses occurred in five of the 41 patients (12.2%) with falciparum malaria who received one-day therapy. Fever resolved after a mean of 45 hours and parasites were absent after a mean of 66 hours. There were small increases in transaminase values (most probably because of the infection) in five patients, but all became normal again within a few days. Halofantrin is a safe drug and is suitable for both therapy and stand-by therapy of resistant Plasmodium infections. Treatment should be repeated after 7 days.
authors.affiliation: Medizinische Klinik und Poliklinik, Klinikum Steglitz, München.
authors.forename: T
authors.initials: T
authors.lastname: Weinke
authors.forename: H D
authors.initials: HD
authors.lastname: Nothdurft
authors.forename: H
authors.initials: H
authors.lastname: Kretschmer
authors.forename: K
authors.initials: K
authors.lastname: Fleischer
authors.forename: T
authors.initials: T
authors.lastname: Löscher
authors.forename: B
authors.initials: B
authors.lastname: Braendli
authors.forename: K
authors.initials: K
authors.lastname: Markwalder
authors.forename: T
authors.initials: T
authors.lastname: Schlunk
authors.forename: R
authors.initials: R
authors.lastname: Clemens
authors.forename: H L
authors.initials: HL
authors.lastname: Bock
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D005858:Germany; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000276:immunology; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000276:immunology; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010616:Phenanthrenes / Q000627:therapeutic use*; D010965:Plasmodium malariae; D011319:Primaquine / Q000627:therapeutic use; D011446:Prospective Studies; D012008:Recurrence; D013557:Switzerland; D013997:Time Factors; D014195:Travel
chemical_list: D000962:Antimalarials; D010616:Phenanthrenes; D011319:Primaquine; C023768:halofantrine